The frontMIND trial is testing a new treatment for patients who have been recently diagnosed with a type of blood cancer called Diffuse Large B-Cell Lymphoma (DLBCL). The study investigates the safety and effectiveness of investigational drug tafasitamab plus lenalidamide. The study aims to determine if addition of the investigational drug to standard therapy for DLBCL improves treatment outcomes for patients compared to standard therapy on its own.
Participants will be randomly assigned to receive investigational drug plus standard chemotherapy, by intravenous infusion, or standard chemotherapy alone. They also undergo the following tests:
Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.
Stephanie Guilas has worked in many departments throughout Mater Hospital Brisbane, however, after 28 years of service, she found her true passion working within Mater Research’s Mothers and Babies...
Working as a research assistant in an immunology research lab, Yvonne Gautam learnt what a clinical trial was after being asked to set up a lab for a Phase Two clinical trial.